Rivenprost

also known as (-)-ono-4819

Small molecule targets PTGER4 via activation

Developed for: ulcerative colitis
Investigated by: Kyoto University, Graduate School of Medicine · National Institute of Biomedical Innovation

today NCT00296556 · Ph 2

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00296556	Feb 2006 → Dec 2007	ulcerative colitis	Kyoto University, Graduate School of Medicine	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Rivenprost	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00296556 ↗
Known as	(-)-ono-4819	ChEMBL registry synonym — accepted as the source's own label CHEMBL303960 ↗
Action	Activate	“Prostanoid EP4 receptor agonist” CHEMBL303960 ↗ 1 “EP4-selective agonist therapy” NCT00296556 ↗
Modality	Small molecule	— CHEMBL303960 ↗
Route	Intravenous	“2 weeks intravenous EP4-selective agonist therapy” NCT00296556 ↗
Target	PTGER4	“Prostanoid EP4 receptor agonist” CHEMBL303960 ↗